Chromatographic Separation and Utilization of Labeled $^{99m}Tc$-Valsartan for Cardiac Imaging

Sanad MH$^1$ and Borai EH$^2$

$^1$Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt
$^2$Analytical Chemistry Department, Hot Labs Center, Atomic Energy Authority, P.O.Box 13759, Cairo, Egypt

Abstract

A procedure was developed for preparing high radiochemical purity $^{99m}Tc$-valsartan with yield of 98%. The complex was prepared by mixing of valsartan with SnCl$_2$.2H$_2$O solution and the pH of the mixture was adjusted to 8 then mixed with a freshly eluted $^{99m}Tc$ O$_4$- ($\approx$400 MBq), shaken at room temperature for 30 min. The radiochemical yield and purity of the labeled product were determined individually by HPLC, paper chromatography and paper electrophoresis. Biodistribution studies were carried out in normal Albino Swiss mice at different time intervals after administration of $^{99m}Tc$-valsartan. The labeled compound cleared from the systemic circulation within 2 h after administration, and the majority of organs showed significant decrease in the uptake of $^{99m}Tc$-valsartan. The heart uptake of $^{99m}Tc$-valsartan was sufficiently high for using this agent as myocardial imaging agent.

Keywords: $^{99m}Tc$-valsartan heart; Losartan; Chromatographic; Analysis; Biodistribution

Introduction

Valsartan is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with Diovan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Valsartan is chemically N-(1-Oxopentyl)-N-[2′-(1H-tetrazol- 5-yl)[1,1′-biphenyl]-4-yl] methyl]-L-valine Figure 1 [1,2]. Valsartan is a potent Angiotensin II receptor blocker. It is mainly used as anti-hypertensive drug [3,4].

Technetium $^{99m}Tc$ is one of the most desirable radionuclides for external imaging in diagnostic nuclear medicine, due to the emission of gamma ray of optimal energy (140 keV), a suitable half-life (6 h), and availability from 99Mo-$^{99m}Tc$ generator systems. In addition, development of $^{99m}Tc$ radiopharmaceuticals for tumor imaging paves the way for therapeutic radiopharmaceuticals with high energy beta emitters 186Re and 188Re because of similar chemical properties between technetium and rhenium.

The present study was mainly oriented to develop a simple method for $^{99m}Tc$ labeling of valsartan. The influence exerted on the reaction rate such as hydrogen ion concentration, substrate and reducing agent amounts, and reaction time have been examined to ensure high radiochemical yield of pure $^{99m}Tc$-valsartan.

Experimental

Materials

Valsartan was gift from Sigma Company for Pharmaceutics. All other chemicals were purchased from Merck and they were reactive grade. The water used is purged with nitrogen gas to give deoxygenated biodistilled water.

Apparatus

Well-type γ-scintillation counter: Scalar Ratemeter SR7 (Nuclear Enterprises Ltd., USA); pH meter: model 601 A digital ion analyzer (Orion Research, USA); ionization chamber: model CRC-15R (Capintec, USA); precision electronic balance: model HA 120 (MAD Enterprises Ltd., USA); pH meter: model CRC-15R (Capintec, USA); precision electronic balance: model HA 120 (MAD Company Ltd., Japan); stirring hot plate: model 210 T Thrmix (Fisher, USA); electrophoresis apparatus: E.C. Corporation (USA).

Labeling method of valsartan

Accurately weighed 2 mg valsartan was dissolved ethanol and...
transferred to an evacuated penicillin vial. Exactly 50 μg SnCl₂·2H₂O solution was added and the pH of the mixture was adjusted to 8 using 0.1N NaOH, then the volume of the mixture was adjusted to one ml by N₂-purged distilled water. One ml of freshly eluted ⁹⁹ᵐTc O₄⁻ (~400 MBq) was added to the above mixture. The reaction mixture was vigorously shaken and allowed to react at room temperature for 30 min to complete the reaction [5,6].

This experiment was conducted to study the different factors that affect the labeling yield such as tin content as (SnCl₂·2H₂O), substrate content, pH of the reaction medium, and reaction time. For labeling process, trials were performed for each factor under investigations to obtain the optimum value. The experiment was repeated with all factors kept at optimum values except the factor under study, till the overall optimal conditions are achieved [7].

**Separation Methods and Recovery of ⁹⁹ᵐTc-valsartan Complex**

**Paper chromatography**

Radiochemical yield of ⁹⁹ᵐTc-valsartan was checked by paper chromatographic method in which, the reaction product was spotted on ascending paper chromatography strips (10×1.5 cm). Free ⁹⁹ᵐTc chromatographic method in which, the reaction product was spotted at complete the reaction [5,6]. The paper electrophoresis pattern revealed that ⁹⁹ᵐTc-valsartan moved sharply toward the anode, suggesting that it has completely ionized negative charge. While ⁹⁹ᵐTc O₄⁻, reduced hydrolyzed technetium remained at the point of spotting. After elution reduced hydrolyzed technetium remains at the origin (Rf=0) while other species migrate with the solvent front (Rf=1).

**Electrophoresis conditions**

Electrophoresis was done with EC-3000 p-series programmable (E.C.apparatus corporation) power and chamber supply units using cellulose acetate strips. The strips were moistened with 0,05M water: ammonium hydroxide mixture (2:5:1) or 5N NaOH as the mobile phase. Reduced hydrolyzed technetium was determined by using ethanol: water: ammonium hydroxide mixture (2: 5: 1) or 5N NaOH as the mobile phase.

After complete development, the strips were dried then cut into 0.5 cm pieces and counted in a well-type γ-scintillation counter. The radiochemical purity was determined by subtracting the sum of the percent of reduced hydrolyzed technetium and free pertechnetate from 100%. The radiochemical yield is the mean value of five experiments.

**HPLC analysis**

HPLC analysis of valsartan solution was done by injection of 10 μl from the reaction mixture into the column (RP-18-250 mm×4.6 mm, 5 m, LiChrosorb) built in HPLC Shimadzu model which consists of pumps LC-9A, Rheohydron injector and UV spectrophotometer detector (SPD-6A) adjusted to the 225 nm wavelength. The column was eluted with a mobile phase phosphate buffer (1%): acetonitrile (40:60 v/v, pH 3.2), as at flow rate 1.0 ml/min. Fractions of 1 ml were collected separately using a fraction collector up to 15 ml and counted in a well-type-scintillation counter [8].

**Stability of ⁹⁹ᵐTc-valsartan**

The stability of ⁹⁹ᵐTc-valsartan was studied in vitro by mixing 1.8 ml of normal human serum and 0.2 ml of ⁹⁹ᵐTc-valsartan and incubated at 37°C for 24 hrs. Exactly 0.2 ml aliquots were withdrawn during the incubation at different time intervals up to 24 hrs and subjected to paper chromatography for determination of the percent of ⁹⁹ᵐTc-valsartan, reduced hydrolyzed technetium and free pertechnetate.

**Animal studies**

The study was approved by the animal ethics committee, Labeled Compound Department, and was in accordance with the guidelines set out by the Egyptian Atomic Energy Authority. For the infection model the animals, Swiss Albino mice (25-30 gm), were intravenously injected with 100 µl (100-150 MBq) of sterile ⁹⁹ᵐTc-valsartan, adjusted to physiological pH via the tail vein and kept alive in metabolic cage for different intervals of time under normal conditions. For quantitative determination of organ distribution, five mice were used for each experiment and the mice were sacrificed at different time post-injection. Samples of fresh blood, bone and muscle were collected in pre-weighed vials and counted. The different organs were removed, counted and compared to a standard solution of the labeled valsartan. The average percent values of the administrated dose/organ were calculated. Blood, bone and muscles were assumed to be 7,10 and 40%, respectively, of the total body weight [9]. Corrections were made for background radiation and physical decay during experiment. Differences in the data were evaluated with the Student t test. Results for P using the 2-tailed test are reported and all the results are given as mean ± SEM. The level of significance was set at P<0.05.

**Results and Discussion**

**Separation performance**

In paper chromatographic method, free ⁹⁹ᵐTc O₄⁻-movied with the solvent front (Rf=1), while ⁹⁹ᵐTc-valsartan and reduced hydrolyzed technetium remained at the point of spotting. After elution reduced hydrolyzed technetium remains at the origin (Rf=0) while other species migrate with the solvent front (Rf=1).

The paper electrophoresis pattern revealed that ⁹⁹ᵐTc-valsartan complex moved towards the anode, indicating that valsartan has partially negative charge by lone pairs of nitrogen atoms while ⁹⁹ᵐTc O₄⁻-movayed sharply toward the anode, suggesting that it has completely ionized negative charge.

HPLC chromatogram was presented in Figure 2 and shows two peaks, one at fraction No. 3, which corresponds to ⁹⁹ᵐTc O₄⁻, while the second peak was collected at fraction No. 6.4 for ⁹⁹ᵐTc-valsartan which was found to coincide with the UV signal.
Factors affecting the labeling yield

Effect of SnCl₂·2H₂O concentration: As shown in Figure 3, the radiochemical yield is highly dependent on the amount of SnCl₂·2H₂O present in the reaction mixture. At 25 µg SnCl₂·2H₂O, the labeling yield of ⁹⁹ᵐTc-valsartan was 77.5% due to the fact that SnCl₂·2H₂O concentration was insufficient to reduce all pertechnetate so the percentage of ⁹⁹ᵐTcO₄⁻ was relatively high (19.0%). The labeling yield significantly increased by increasing the amount of SnCl₂·2H₂O from 25 to 50 µg (optimum content), at which a maximum labeling yield of 98% was obtained. By increasing the amount of SnCl₂·2H₂O above the optimum concentration value, the labeling yield decreased again because the excess SnCl₂·2H₂O was converted to colloid (51.2% at 200 µg SnCl₂·2H₂O) [10-12].

Effect of valsartan amount: As shown in Figure 4, the labeling yield of ⁹⁹ᵐTc-valsartan complex was 70.0% at 1 mg valsartan and increased with increasing the amount of valsartan till reaching the maximum value of 98% at 2 mg. The formed complex remained stable with increasing the amount of valsartan up to 10 mg. So the optimum amount of valsartan was kept at 2 mg [13,14].

Effect of pH of the reaction mixture: The results in Figure 5 demonstrated that at pH 4 the labeling yield of ⁹⁹ᵐTc-valsartan complex was relatively low reaching to 60.0%. The yield increased with increasing the pH of the reaction mixture where at pH 8 gave the maximum labeling yield of 98%. By increasing the pH greater than 8, the labeling yield decreased again till it became 45.8% at pH 10 where colloid material becomes the main impurity (40.5% at pH 10). After pH 10 more colloidal solutions are formed [15].

Effect of reaction time: Figure 6 describes the effect of reaction time on the radiochemical purity of ⁹⁹ᵐTc-valsartan complex. At 1 min post labeling, the yield was relatively moderate reached to 86.0% which increased with time till reaching to its maximum value of 98% at 30 min. The yield remains stable at 98.2% for a time up to 2 hrs [16].

Stability test: As shown in Figure 7, in-vitro stability of ⁹⁹ᵐTc-valsartan was studied in order to determine the suitable time for injection to avoid the formation of the undesired products that result from the decomposition of the complex. These undesired radioactive products might be accumulated in non-target organs. The results of stability test showed that the ⁹⁹ᵐTc-valsartan is stable for 24 hours at 37°C resulted in a small release of radioactivity (n=5 experiments) from the ⁹⁹ᵐTc-valsartan. The results was determined by paper chromatography which showed that the stability decreased from 98 to 92.0% [17].

Biodistribution of ⁹⁹ᵐTc-valsartan in normal mice: Biodistribution experiments showed that ⁹⁹ᵐTc-valsartan was distributed rapidly in blood, heart, kidneys, liver and intestine at 15 min post injection. After
Table 1: Biodistribution of 99mTc-valsartan in normal mice. Mean ± SD (mean of five experiments).

| Organs and Body Fluids | Percent I.D./gram Organ | Time post injection | 15 min | 1/2 hr | 1 hr | 2 hr |
|------------------------|-------------------------|--------------------|--------|--------|-----|-----|
| Blood                  |                         |                    | 14.9 ± 0.19 | 11.8 ± 0.80 | 5.8 ± 0.29 | 2.7 ± 0.44 |
| Bone                   |                         |                    | 1.9 ± 0.78 | 2.7 ± 0.64 | 2.8 ± 0.19 | 1.5 ± 0.09 |
| Muscle                 |                         |                    | 0.87 ± 0.01 | 1.2 ± 0.02 | 1.3 ± 0.13 | 1.15 ± 0.11 |
| Liver                  |                         |                    | 4.9 ± 0.18 | 9.7 ± 0.17 | 6.1 ± 0.48 | 2.8 ± 0.39 |
| Lung                   |                         |                    | 3.5 ± 0.16 | 2.18 ± 0.33 | 2.21 ± 0.31 | 1.9 ± 0.02 |
| Heart                  |                         |                    | 9.1 ± 0.12 | 11.2 ± 0.27 | 5.9 ± 0.32 | 2.4 ± 0.41 |
| Stomach                |                         |                    | 2.8 ± 0.29 | 2.9 ± 0.16 | 1.5 ± 0.16 | 0.9 ± 0.01 |
| Intestine              |                         |                    | 4.1 ± 0.17 | 5.8 ± 0.28 | 2.3 ± 0.13 | 1.4 ± 0.12 |
| Kidney                 |                         |                    | 8.3 ± 0.20 | 13.4 ± 0.39 | 5.9 ± 0.23 | 3.1 ± 0.13 |
| Spleen                 |                         |                    | 1.2 ± 0.02 | 1.5 ± 0.13 | 1.0 ± 0.11 | 1.3 ± 0.20 |

*significantly different from the previous value of each organ using unpaired Student's t-test (P<0.05).

Table 2: Biodistribution of 99mTc-losartan in normal mice. Mean ± SD (mean of 10 experiments).

| Organs and Body Fluids | Percent I.D./gram organ | Time post injection | 15 min | 1/2 hr | 1 hr | 2 hr |
|------------------------|-------------------------|--------------------|--------|--------|-----|-----|
| Blood                  |                         |                    | 12.2 ± 1.10 | 11.6 ± 0.20 | 7.2 ± 0.04 | 3.7 ± 0.30 |
| Bone                   |                         |                    | 2.0 ± 0.05 | 3.2 ± 0.10 | 2.3 ± 0.10 | 2.2 ± 0.02 |
| Muscle                 |                         |                    | 0.5 ± 0.01 | 0.5 ± 0.02* | 1.3 ± 0.10 | 0.7 ± 0.02* |
| Liver                  |                         |                    | 5.1 ± 0.05 | 6.5 ± 0.15 | 3.5 ± 0.06 | 2.0 ± 0.02 |
| Lung                   |                         |                    | 4.3 ± 0.10 | 5.8 ± 0.12* | 3.2 ± 0.20 | 2.1 ± 0.01* |
| Heart                  |                         |                    | 8.2 ± 0.80 | 6.9 ± 0.30* | 5.2 ± 0.01 | 1.8 ± 0.04* |
| Stomach                |                         |                    | 5.2 ± 0.90 | 7.2 ± 0.60 | 7.6 ± 0.16* | 7.7 ± 0.2 |
| Intestine              |                         |                    | 5.4 ± 0.50 | 7.2 ± 0.30* | 3.1 ± 0.10* | 1.9 ± 0.03* |
| Kidney                 |                         |                    | 6.9 ± 0.40 | 9.0 ± 0.60 | 4.1 ± 0.30 | 2.1 ± 0.06* |
| Spleen                 |                         |                    | 1.7 ± 0.02 | 3.0 ± 0.14* | 3.0 ± 0.16 | 1.1 ± 0.20* |

The heart uptake was 9.1, 11.2, and 5.9% ID/g at 15 min, 30 min, and 1 h, respectively. This uptake may be useful for radioimaging of the heart. Thus, this procedure for 99mTc labeling of valsartan at room temperature (25 ± 1°C) in reasonable time (30 min) using SnCl2·2H2O as a reducing agent at pH 8 has been successively examined with high yield reached to 98%. The biodistribution of labeled valsartan in normal mice reflects the rapid heart uptake which is higher than that of 99mTc-losartan [18-21] which have maximum heart uptake of (8.2% at 15 min). The uptake percent of 99mTc-valsartan is sufficient for myocardial imaging (Table 2).

Conclusion

Valsartan can be labeled easily with 99mTc using 50 μg stannous chloride (SnCl2·2H2O) as a reducing agent and 2 mg valsartan at pH 8 for 30 min at room temperature to give 99mTc-valsartan complex with a radiochemical yield of 98%. Biodistribution studies showed that the uptake of 99mTc-valsartan in the heart (11.2% ± 0.20) at 30 min post injection is higher than that of 99mTc-losartan (8.2% ± 0.80) at 15 min post injection. Furthermore, 99mTc-valsartan could be considered as a novel radiopharmaceutical for heart imaging.

References

1. Budavari S (2006) The Merck index (Edition 14), Merck and Co. Press, NJ.
2. O’Neil MJ, Smitha, Heckelman PE, Kinneary JF (2006) The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals (Edition 14);1767.
3. Criscione L, Bradely W, Buhmayer P, Whitebread S, Glazer R, et al. (1995) Clinical advantage of valsartan. Drug Rev 13: 230.
4. Oparil S, Dyke S, Harris F, Kief J, James D, et al. (1996) The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 18: 797-810.
5. BoydeRE (1986) Technetium generators: status and prospects, Nucl Spectrum 2: 18.
6. Huston JS, George AJ, Adams GP, Stafford WF, Janar F, et al. (1996) Single-chain Fv radio immuno targeting. Q J Nucl Med 40: 320-333.
7. Nitin D, Nithi D, Mayank M, Upendra B, Praveen S (2012) Asian Journal of Pharmacy and Medical Science. 2 (1): 23.
8. Motaleb MA (2001), Synthesis and evaluation of some 99mTc-Complexes; applied in nuclear medicine, Ph.D. Thesis, Faculty of Science, Ain-Shams University, Cairo, Egypt.
9. Liu FEI, Youfeng HE, Luo Z (2004) AEA, Austria, Technical Reports Series No 426,37.
10. Gündor T, Chen Y, Golla R, Ma Z, Corte JR, et al. (2006) Synthesis and characterization of 3-aryquinazolinone and 3-aryquinazolinoethinone derivatives as selective estrogen receptor beta modulators. J Med Chem 49: 2440-2455.
11. Schlösser R, Schlegel S, Hiemke C, Nickel O, Bockisch A, et al. (1997) [123]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. Psychiatry Res 75: 103-114.
12. Sanad MH (2007) Synthesis and labeling of some organic compounds with one of the most radioactive isotope Ph.D.Thesis, Chemistry Department, Faculty of Science, Ain-Shams University, Cairo, Egypt.
13. Hanson J, Reynaud D, Qiao N, Devel P, Moray AL, et al. (2006) Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isomers of the human thromboxane receptor. J Med Chem 49: 3701-3709.
14. Motaleb, MA, Mustapha ME, Ibrahim, IT (2011) J Radioanal Nucl Chem
15. Waterhouse RN, Mardon K, O’Brien JC (1997) Synthesis and preliminary evaluation of [123I]-(-4-cyanobenzyl)-4-[[trans-i dopropen-2-yloxymethyl] yl]piperidine: a novel high affinity sigma receptor radioligand for SPECT. Nucl Med Biol 24: 45-51.
16. Motaleb MA, Sanad MH (2012) Arab J Nucl Sci Appli; 45: 71.
17. Ibrahim IT, Sanad MH (2013) J Radiochemistry, 55: 336.
18. Sanad MH, Ibrahim IT (2013) J Radiochemistry 55 : 341.
19. Amin AM, Sanad MH, Abd-Elhalim SM (2013) Journal of Radiochemistry55: 624.
20. Motaleb MA, Kolay MT EI, Rashed HM, Abd El-Bary A (2011). Rad Anl, Nucl Chem; 289: 915.
21. Sanad MH (2014) Journal of Analytical Science and Technology; 5: 23.